Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Anti-Nuclear Antibodies & Nuclear Molecules in Systemic Lupus Erythematosus

Katie Robinson  |  Issue: October 2024  |  September 6, 2024

“Sex is another major genetic influence on pathogenesis that may reflect the effects of hormones and the number of X chromosomes and the pattern of X chromosome inactivation,” Dr. Pisetsky writes.

Case Review

The hypothetical patient showed features of the SLE model.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Along with both her sex and an African ancestry placing her at high risk, the hypothetical patient had evidence of a genetic predisposition based on her family history—a sister with rheumatoid arthritis and an aunt with lupus. She also had a cluster pattern of ANA expression associated with nephritis, along with anti-DNA antibodies and anti-RBP antibodies, which contribute to heightened immune activity and nephritis. Due to proteinuria, a renal biopsy would likely show evidence of immune deposition.

If treatment with a combination of glucocorticoid steroids and mycophenolate mofetil was effective, laboratory testing would show a decrease in anti-DNA antibody levels and an increase in complement levels, Dr. Pisetsky suggests.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

He explains that SLE agents can be placed at key steps in the model. Specifically, “steroids can decrease inflammation and cytokine production; hydroxychloroquine can affect endosomal function and signaling by TLR-9; hydroxychloroquine may also affect the generation of NETs; mycophenolate can affect B cell function, as can belimumab; and rituximab can eliminate CD20+ B cells without effects on plasma cells. Anifrolumab can inhibit responses to interferon by blocking the receptor.” He adds that chimeric antigen receptor T cells could be considered to eliminate B cells if the patient is unresponsive to treatment.

Katie Robinson is a medical writer based in New York.


References

  1. Bucala R, Solomon DH. Immunology for the rheumatologist: A&R introduces a new problem-based immunology review series with great educational potential. Arthritis Rheumatol. 2024. Jan;76(1):9–10.
  2. Pisetsky DS. Unique interplay between antinuclear antibodies and nuclear molecules in the pathogenesis of systemic lupus erythematosus. Arthritis Rheumatol. 2024;76(9):1334–1343.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:ANAanti-neutrophil antibodyImmunologySLE Resource Center

Related Articles

    A 52-Year-Old Lupus Paper Remains Important Today

    December 14, 2020

    Over 50 years ago, an article appeared in The New England Journal of Medicine: “Immunologic Factors and Clinical Activity in Systemic Lupus Erythema­tosus.”1 Written by a young postdoctoral fellow, Peter H. Schur, MD, and colleagues, the article synthesized important work in the field at the time. What follows is a discussion of the historical context…

    Laboratory Testing for Diagnosis, Management of Patients with Rheumatic Disease

    December 1, 2014

    A review of data on antinuclear antibodies and tests for rheumatoid arthritis

    T Cells in Systemic Lupus Erythematosus

    August 1, 2011

    Progress toward targeted therapy

    How a Nuclear Molecule Alarms the Immune System

    August 1, 2011

    The role of HMGB1 in the pathogenesis of lupus nephritis

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences